{
"ranked_hypotheses": [
{
"rank": 1,
"title": "FcγRIIB Upregulation Failure Permits Anti-AQP4 B Cell Escape",
"mechanism": "AQP4-specific B cells in healthy individuals upregulate inhibitory FcγRIIB (CD32) upon chronic AQP4 engagement, recruiting SHP-1 to attenuate BCR signaling; NMO patients exhibit impaired FcγRIIB upregulation due to defective BTK/CARD11 signaling.",
"target_gene": "FCGR2B",
"confidence_score": 0.65,
"novelty_score": 0.55,
"feasibility_score": 0.60,
"impact_score": 0.85,
"composite_score": 0.67,
"testable_prediction": "Compare FcγRIIB expression and SHP-1 recruitment in AQP4-specific B cells from NMO patients vs. healthy controls upon BCR stimulation in vitro.",
"skeptic_concern": "AQP4 is CNS-restricted with minimal systemic access, challenging the premise of chronic peripheral AQP4 engagement required for FcγRIIB upregulation."
},
{
"rank": 2,
"title": "Regulatory B Cell (Breg) IL-10 Production Suppresses Anti-AQP4 Responses",
"mechanism": "IL-10-producing Bregs in healthy individuals actively suppress AQP4-specific B cell activation and plasma cell differentiation through PD-L1 and IL-10 secretion; NMO patients have reduced Breg frequency or functional impairment.",
"target_gene": "IL10",
"confidence_score": 0.60,
"novelty_score": 0.70,
"feasibility_score": 0.65,
"impact_score": 0.75,
"composite_score": 0.67,
"testable_prediction": "Quantify IL-10+ Breg frequency and suppressive function in NMO patients vs. healthy controls and test whether IL-10 receptor blockade breaks tolerance in vitro.",
"skeptic_concern": "Whether Bregs preferentially target AQP4-specific B cells among diverse autoreactive specificities remains unclear."
},
{
"rank": 3,
"title": "Anergic B Cell Receptor Desensitization Maintains Anti-AQP4 Tolerance",
"mechanism": "AQP4-specific B cells undergo anergy induction through chronic low-affinity self-antigen exposure, resulting in reduced BCR signaling responsiveness and elevated SHP-1 expression; NMO patients fail to establish or maintain this anergic state.",
"target_gene": "PTPN6 (SHP-1)",
"confidence_score": 0.55,
"novelty_score": 0.60,
"feasibility_score": 0.70,
"impact_score": 0.70,
"composite_score": 0.62,
"testable_prediction": "Measure BCR calcium flux and SHP-1 expression in AQP4-specific B cells sorted from healthy donors vs. NMO patients to assess anergy markers.",
"skeptic_concern": "Anergy mechanisms typically require continuous antigen exposure, raising the same systemic AQP4 access concern as Hypothesis 1."
}
],
"consensus_points": [
"B cell tolerance to AQP4 is actively maintained rather than passively absent in healthy individuals",
"NMO patients exhibit measurable defects in B cell tolerance mechanisms",
"FcγRIIB signaling pathway is a credible therapeutic target for restoring tolerance"
],
"dissent_points": [
"Whether AQP4 or AQP4 fragments reach peripheral lymphoid organs in sufficient quantities to drive tolerance mechanisms remains mechanistically unexplained",
"Whether the primary defect is B cell-intrinsic (FcγRIIB dysregulation) vs. B cell-extrinsic (T cell help, regulatory mechanisms) is unresolved"
],
"debate_summary": "Theorist proposes FcγRIIB dysregulation as the primary tolerance mechanism, supported by established autoimmunity models but challenged by the skeptic's valid concern that CNS-restricted AQP4 cannot drive peripheral B cell tolerance. The expert prioritizes this hypothesis for translational potential despite the antigen access gap. Alternative tolerance mechanisms (Breg-mediated suppression, anergy) offer complementary or compensatory pathways that may resolve the antigen access paradox while maintaining therapeutic relevance."
}